Genetic polymorphisms of FOXP3 in Italian patients with systemic sclerosis

Immunology Letters

Volumn 152, Issue 2, 2013, Pages 109-113

  D'Amico, Fabio ^a   Skarmoutsou, Evangelia ^a   Marchini, Maurizio ^b   Malaponte, Grazia ^a   Caronni, Monica ^b   Scorza, Raffaella ^b   Mazzarino, Maria Clorinda ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Anticentromere antibodies; Autoimmunity; FOXP3 gene; Single nucleotide polymorphisms; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; AUTOANTIBODY; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ALLELE; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FOXP3 GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; ITALIAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; CENTROMERE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; IMMUNOLOGY; ITALY; MIDDLE AGED; PHENOTYPE;

AUTOANTIBODIES; CASE-CONTROL STUDIES; CENTROMERE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCLERODERMA, SYSTEMIC;

EID: 84879132270     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.05.006     Document Type: Article

References (36)

1. Katsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis. Annu Rev Pathol Mech Dis 2011, 6:509-537.
2. Broen J.C., Coenen M.J., Radstake T.R. Deciphering the genetic background of sistemic sclerosis. Expert Rev Clin Immunol 2011, 7:449-462.
3. Agarwal S.K., Reveille J.D. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol 2010, 22:133-138.
4. Gourh P., Agarwal S.K., Divecha D., Assassi S., Paz G., Arora-Singh R.K., et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009, 60:3794-3806.
5. Ito I., Kawaguchi Y., Kawasaki A., Hasegawa M., Ohashi J., Kawamoto M., et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010, 62:890-895.
6. Diaz-Gallo L.M., Gourh P., Broen J., Simeon C., Fonollosa V., Ortego-Centeno N., et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011, 70:454-462.
7. Coustet B., Bouaziz M., Dieudé P., Guedj M., Bossini-Castillo L., Agarwal S., et al. Independent replication and metaanalysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. J Rheumatol 2012, 39:997-1003.
8. Sharif R., Mayes M.D., Tan F.K., Gorlova O.Y., Hummers L.K., Shah A.A., et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis 2012, 71:1197-1202.
9. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
10. Park O., Grishina I., Leung P.S., Gershwin M.E., Prindiville T. Analysis of the Foxp3/scurfin gene in Crohn's disease. Ann NY Acad Sci 2005, 1051:218-228.
11. Ban Y., Tozaki T., Tobe T., Ban Y., Jacobson E.M., Concepcion E.S., et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts. J Autoimmun 2007, 28:201-207.
12. Gao L., Li K., Li F., Li H., Liu L., Wang L., et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci 2010, 57:51-56.
13. Inoue N., Watanabe M., Morita M., Tomizawa R., Akamizu T., Tatsumi K., et al. Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid diseases. Clin Exp Immunol 2010, 162:402-406.
14. Lin Y.C., Lee J.H., Wu A.S., Tsai C.Y., Yu H.H., Wang L.C., et al. Association of single-nucleotide polymorphisms in FOXP3 gene with systemic lupus erythematosus susceptibility: a case-control study. Lupus 2011, 20:137-143.
15. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39:537-545.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
17. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 1988, 15:202-205.
18. Dupont W.D., Plummer W.D. Power and sample size calculations for studies involving linear regression. Controlled Clin Trials 1998, 19:589-601.
19. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007, 8:277-284.
20. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32.
21. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., et al. Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest 2002, 109:131-140.
22. Kriegel M.A., Lohmann T., Gabler C., Blank N., Kalden J.R., Lorenz H-M. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004, 199:1285-1291.
23. Huan J., Culbertson N., Spencer L., Bartholomew R., Burrows G.G., Chou Y.K., et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005, 81:45-52.
24. Nistala K., Wedderburn L.R. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology 2009, 48:602-606.
25. Mathian A., Parizot C., Dorgham K., Trad S., Arnaud L., Larsen M., et al. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 2012, 71:1227-1234.
26. Banica L., Besliu A., Pistol G., Stavaru C., Ionescu R., Forsea A.M., et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009, 42:41-49.
27. Fenoglio D., Battaglia F., Parodi A., Stringara S., Negrini S., Panico N., et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011, 139:249-257.
28. Papp G., Horvath I.F., Barath S., Gyimesi E., Spika S., Szodoray P., et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneus systemic sclerosis. Scand J Rheumatol 2011, 40:205-210.
29. Antiga E., Quaglino P., Bellandi S., Volpi W., Del Bianco E., Comessatti A., et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010, 162:1056-1063.
30. Radstake T.R., van Bon L., Broen J., Wenink M., Santegoets K., Deng Y., et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS ONE 2009, 4:e5981.
31. Slobodin G., Ahmad M.S., Rosner I., Peri R., Rozenbaum M., Kessel A., et al. Regulatory T cells (CD4+CD25brighFoxP+) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010, 261:77-80.
32. Rodriguez-Reyna T.S., Furuzawa-Carballeda J., Cabiedes J., Fajardo-Hermosillo L.D., Martinez-Reyes C., Diaz-Zamudio M., et al. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a crosssectional study. Rheumatol Int 2012, 32:2653-2660.
33. Klein S., Kretz C.C., Ruland V., Stumpf C., Haust M., Hartschuh W., et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 2011, 70:1475-1481.
34. Furuzawa-Carballeda J., Ortíz-Ávalos M., Lima G., Jurado-Santa Cruz F., Llorente L. Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases Foxp3-expressing cells in localized scleroderma. Clin Exp Dermatol 2012, 37:599-609.
35. Gourh P., Arnett F.C., Tan F.K., Assassi S., Divecha D., Paz G., et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010, 69:550-555.
36. Martin J-E., Carmona F.D., Broen J.C.A., Simeon C.P., Vonk M.C., Carreira P., et al. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes Immun 2012, 13:191-196.